Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
REGN · against 588 other Healthcare companies listed in US-listed
Ranked #121 of 589 · scores higher than 79% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 60–69, including REGN · Click a bar to see the companies
Mainly thanks to its earnings yield and free cash flow yield, which are stronger than most Healthcare peers.
| Metric | REGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 4.1% | -4.3% | 86% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 5.1% | -0.8% | 70% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 3.6% | -2.3% | 75% | 20% | |
| Book yieldHigher is better · 587 reported | 32.5% | 25.9% | 58% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 118 | 2.2B USD | 62 | 37 | |
| 121 | 36.8B USD |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 46 |
| 121 | 1.2B USD | 61 | 67 |
| 121 | 10.6B USD | 61 | 64 |
| 121 | 100.2B USD | 61 | 68 |
| 125 | 21.4B USD | 60 | 67 |
| 125 | 249.4B USD | 60 | 55 |
| 125 | 1.1B USD | 60 | 43 |
| 125 | 43.2B USD | 60 | 45 |